JP2019528042A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019528042A5 JP2019528042A5 JP2019500553A JP2019500553A JP2019528042A5 JP 2019528042 A5 JP2019528042 A5 JP 2019528042A5 JP 2019500553 A JP2019500553 A JP 2019500553A JP 2019500553 A JP2019500553 A JP 2019500553A JP 2019528042 A5 JP2019528042 A5 JP 2019528042A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- bont
- polypeptide
- amino acid
- acid sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108090000765 processed proteins & peptides Proteins 0.000 claims 25
- 108030001720 Bontoxilysin Proteins 0.000 claims 24
- 231100001103 botulinum neurotoxin Toxicity 0.000 claims 24
- 229920001184 polypeptide Polymers 0.000 claims 23
- 102000004196 processed proteins & peptides Human genes 0.000 claims 23
- 125000003275 alpha amino acid group Chemical group 0.000 claims 12
- 230000035772 mutation Effects 0.000 claims 9
- 238000006467 substitution reaction Methods 0.000 claims 9
- 101000761935 Clostridium botulinum Botulinum neurotoxin type X Proteins 0.000 claims 5
- 102000039446 nucleic acids Human genes 0.000 claims 5
- 108020004707 nucleic acids Proteins 0.000 claims 5
- 150000007523 nucleic acids Chemical class 0.000 claims 5
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- 241000193155 Clostridium botulinum Species 0.000 claims 3
- 206010044074 Torticollis Diseases 0.000 claims 3
- 206010013952 Dysphonia Diseases 0.000 claims 2
- 206010067672 Spasmodic dysphonia Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 208000035475 disorder Diseases 0.000 claims 2
- 210000003205 muscle Anatomy 0.000 claims 2
- 230000001537 neural effect Effects 0.000 claims 2
- 230000028327 secretion Effects 0.000 claims 2
- 201000002849 spasmodic dystonia Diseases 0.000 claims 2
- 230000001148 spastic effect Effects 0.000 claims 2
- 206010002153 Anal fissure Diseases 0.000 claims 1
- 208000016583 Anus disease Diseases 0.000 claims 1
- 206010010904 Convulsion Diseases 0.000 claims 1
- 208000019505 Deglutition disease Diseases 0.000 claims 1
- 208000012661 Dyskinesia Diseases 0.000 claims 1
- 208000014094 Dystonic disease Diseases 0.000 claims 1
- 208000000289 Esophageal Achalasia Diseases 0.000 claims 1
- 206010063006 Facial spasm Diseases 0.000 claims 1
- 208000009531 Fissure in Ano Diseases 0.000 claims 1
- 206010019233 Headaches Diseases 0.000 claims 1
- 208000004095 Hemifacial Spasm Diseases 0.000 claims 1
- 208000036066 Hemophagocytic Lymphohistiocytosis Diseases 0.000 claims 1
- 208000032672 Histiocytosis haematophagic Diseases 0.000 claims 1
- 206010020751 Hypersensitivity Diseases 0.000 claims 1
- 208000015592 Involuntary movements Diseases 0.000 claims 1
- 206010023644 Lacrimation increased Diseases 0.000 claims 1
- 208000007101 Muscle Cramp Diseases 0.000 claims 1
- 208000000693 Neurogenic Urinary Bladder Diseases 0.000 claims 1
- 206010029279 Neurogenic bladder Diseases 0.000 claims 1
- 208000008589 Obesity Diseases 0.000 claims 1
- 206010030136 Oesophageal achalasia Diseases 0.000 claims 1
- 208000002193 Pain Diseases 0.000 claims 1
- 208000016222 Pancreatic disease Diseases 0.000 claims 1
- 206010061334 Partial seizures Diseases 0.000 claims 1
- 208000036496 Pelvic floor dyssynergia Diseases 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 206010039424 Salivary hypersecretion Diseases 0.000 claims 1
- 208000005392 Spasm Diseases 0.000 claims 1
- 208000004350 Strabismus Diseases 0.000 claims 1
- 206010044565 Tremor Diseases 0.000 claims 1
- 201000000621 achalasia Diseases 0.000 claims 1
- 230000001476 alcoholic effect Effects 0.000 claims 1
- 208000026935 allergic disease Diseases 0.000 claims 1
- 230000007815 allergy Effects 0.000 claims 1
- 150000001413 amino acids Chemical class 0.000 claims 1
- 201000002898 anismus Diseases 0.000 claims 1
- 230000036528 appetite Effects 0.000 claims 1
- 235000019789 appetite Nutrition 0.000 claims 1
- 206010005159 blepharospasm Diseases 0.000 claims 1
- 230000000744 blepharospasm Effects 0.000 claims 1
- 206010006514 bruxism Diseases 0.000 claims 1
- 210000004027 cell Anatomy 0.000 claims 1
- 206010008129 cerebral palsy Diseases 0.000 claims 1
- 201000002866 cervical dystonia Diseases 0.000 claims 1
- 206010009887 colitis Diseases 0.000 claims 1
- 239000002537 cosmetic Substances 0.000 claims 1
- 230000004064 dysfunction Effects 0.000 claims 1
- 208000010118 dystonia Diseases 0.000 claims 1
- 210000003414 extremity Anatomy 0.000 claims 1
- 230000002496 gastric effect Effects 0.000 claims 1
- 210000004907 gland Anatomy 0.000 claims 1
- 231100000869 headache Toxicity 0.000 claims 1
- 208000014752 hemophagocytic syndrome Diseases 0.000 claims 1
- 230000001771 impaired effect Effects 0.000 claims 1
- 208000018197 inherited torticollis Diseases 0.000 claims 1
- 230000004317 lacrimation Effects 0.000 claims 1
- 230000017311 musculoskeletal movement, spinal reflex action Effects 0.000 claims 1
- 210000002569 neuron Anatomy 0.000 claims 1
- 235000020824 obesity Nutrition 0.000 claims 1
- 201000002851 oromandibular dystonia Diseases 0.000 claims 1
- 208000024691 pancreas disease Diseases 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 102000040430 polynucleotide Human genes 0.000 claims 1
- 108091033319 polynucleotide Proteins 0.000 claims 1
- 239000002157 polynucleotide Substances 0.000 claims 1
- 239000004293 potassium hydrogen sulphite Substances 0.000 claims 1
- 102220040233 rs79219465 Human genes 0.000 claims 1
- 208000026451 salivation Diseases 0.000 claims 1
- 210000001364 upper extremity Anatomy 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022076994A JP7402916B2 (ja) | 2016-07-08 | 2022-05-09 | 新規ボツリヌスニューロトキシンおよびその誘導体 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662360239P | 2016-07-08 | 2016-07-08 | |
| US62/360,239 | 2016-07-08 | ||
| PCT/US2017/041255 WO2018009903A2 (en) | 2016-07-08 | 2017-07-07 | A novel botulinum neurotoxin and its derivatives |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022076994A Division JP7402916B2 (ja) | 2016-07-08 | 2022-05-09 | 新規ボツリヌスニューロトキシンおよびその誘導体 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019528042A JP2019528042A (ja) | 2019-10-10 |
| JP2019528042A5 true JP2019528042A5 (https=) | 2020-08-20 |
| JP7158371B2 JP7158371B2 (ja) | 2022-10-21 |
Family
ID=59384231
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019500553A Active JP7158371B2 (ja) | 2016-07-08 | 2017-07-07 | 新規ボツリヌスニューロトキシンおよびその誘導体 |
| JP2022076994A Active JP7402916B2 (ja) | 2016-07-08 | 2022-05-09 | 新規ボツリヌスニューロトキシンおよびその誘導体 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022076994A Active JP7402916B2 (ja) | 2016-07-08 | 2022-05-09 | 新規ボツリヌスニューロトキシンおよびその誘導体 |
Country Status (22)
| Country | Link |
|---|---|
| US (2) | US11286473B2 (https=) |
| EP (2) | EP3481852B1 (https=) |
| JP (2) | JP7158371B2 (https=) |
| KR (1) | KR102530925B1 (https=) |
| CN (1) | CN109803980B (https=) |
| AU (2) | AU2017292922B9 (https=) |
| BR (1) | BR112019000278A2 (https=) |
| CA (1) | CA3030155A1 (https=) |
| DK (1) | DK3481852T5 (https=) |
| EA (1) | EA201990229A1 (https=) |
| ES (1) | ES2939001T3 (https=) |
| FI (1) | FI3481852T3 (https=) |
| HU (1) | HUE061429T2 (https=) |
| IL (2) | IL298102B2 (https=) |
| MX (1) | MX2019000151A (https=) |
| NZ (1) | NZ749810A (https=) |
| PL (1) | PL3481852T3 (https=) |
| PT (1) | PT3481852T (https=) |
| SG (2) | SG10201912102WA (https=) |
| UA (1) | UA125965C2 (https=) |
| WO (1) | WO2018009903A2 (https=) |
| ZA (1) | ZA201900341B (https=) |
Families Citing this family (63)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2825370A1 (en) | 2010-12-22 | 2012-06-28 | President And Fellows Of Harvard College | Continuous directed evolution |
| WO2014079495A1 (en) | 2012-11-21 | 2014-05-30 | Syntaxin Limited | Methods for the manufacture of proteolytically processed polypeptides |
| WO2015134121A2 (en) | 2014-01-20 | 2015-09-11 | President And Fellows Of Harvard College | Negative selection and stringency modulation in continuous evolution systems |
| WO2016077052A2 (en) | 2014-10-22 | 2016-05-19 | President And Fellows Of Harvard College | Evolution of proteases |
| WO2016168631A1 (en) | 2015-04-17 | 2016-10-20 | President And Fellows Of Harvard College | Vector-based mutagenesis system |
| EP3285800B1 (en) * | 2015-04-24 | 2019-09-18 | Consiglio Nazionale Delle Ricerche | A new therapeutic use of the botulinum neurotoxin serotype a |
| US10676723B2 (en) | 2015-05-11 | 2020-06-09 | David Gordon Bermudes | Chimeric protein toxins for expression by therapeutic bacteria |
| WO2017015545A1 (en) | 2015-07-22 | 2017-01-26 | President And Fellows Of Harvard College | Evolution of site-specific recombinases |
| US11524983B2 (en) | 2015-07-23 | 2022-12-13 | President And Fellows Of Harvard College | Evolution of Bt toxins |
| WO2017019895A1 (en) | 2015-07-30 | 2017-02-02 | President And Fellows Of Harvard College | Evolution of talens |
| IL310721B2 (en) | 2015-10-23 | 2025-11-01 | Harvard College | Nucleobase editors and uses thereof |
| GB201607901D0 (en) * | 2016-05-05 | 2016-06-22 | Ipsen Biopharm Ltd | Chimeric neurotoxins |
| SG11201809903WA (en) * | 2016-05-16 | 2018-12-28 | Harvard College | Method for purification and activation of botulinum neurotoxin |
| EP3481852B1 (en) | 2016-07-08 | 2022-12-07 | Children's Medical Center Corporation | A novel botulinum neurotoxin and its derivatives |
| US11129906B1 (en) | 2016-12-07 | 2021-09-28 | David Gordon Bermudes | Chimeric protein toxins for expression by therapeutic bacteria |
| US11040090B2 (en) * | 2016-12-08 | 2021-06-22 | Prime Bio, Inc | Botulinum neurotoxin compositions |
| US11447809B2 (en) | 2017-07-06 | 2022-09-20 | President And Fellows Of Harvard College | Evolution of tRNA synthetases |
| US12060553B2 (en) | 2017-08-25 | 2024-08-13 | President And Fellows Of Harvard College | Evolution of BoNT peptidases |
| WO2019056002A1 (en) | 2017-09-18 | 2019-03-21 | President And Fellows Of Harvard College | CONTINUOUS EVOLUTION FOR STABILIZED PROTEINS |
| WO2019067815A2 (en) * | 2017-09-29 | 2019-04-04 | Children's Medical Center Corporation | NEUROTOXIN-LIKE TOXIN AND USES THEREOF |
| WO2019152380A1 (en) | 2018-01-30 | 2019-08-08 | Children's Medical Center Corporation | Production of botulinum neurotoxins using bacillus systems |
| WO2019241649A1 (en) | 2018-06-14 | 2019-12-19 | President And Fellows Of Harvard College | Evolution of cytidine deaminases |
| GB201815817D0 (en) | 2018-09-28 | 2018-11-14 | Ispen Biopharm Ltd | Clostridial neurotoxins comprising and exogenous activation loop |
| CA3111674A1 (en) | 2018-09-28 | 2020-04-02 | Ipsen Biopharm Limited | Cell-based clostridal neurotoxin assays |
| GB201815844D0 (en) | 2018-09-28 | 2018-11-14 | Ipsen Biopharm Ltd | Therapeutic & comestic uses of botulinum neurotoxin serotype e |
| GB201900621D0 (en) | 2019-01-16 | 2019-03-06 | Ipsen Biopharm Ltd | Labelled polypeptides |
| US20220220466A1 (en) * | 2019-04-17 | 2022-07-14 | Children's Medical Center Corporation | Catalytically inactive botulinum neurotoxin-like toxins and uses thereof |
| GB201907016D0 (en) | 2019-05-17 | 2019-07-03 | Ipsen Biopharm Ltd | Screening method to determine suitability for participation in a clinical trial |
| US20220259269A1 (en) * | 2019-07-15 | 2022-08-18 | President And Fellows Of Harvard College | Evolved botulinum neurotoxins and uses thereof |
| GB201914034D0 (en) | 2019-09-30 | 2019-11-13 | Ipsen Biopharm Ltd | Treatment of neurological disorders |
| CN110938150B (zh) * | 2019-12-16 | 2021-08-31 | 中国人民解放军军事科学院军事医学研究院 | E型肉毒毒素重组l-hn抗原的制备方法及其应用 |
| KR102610179B1 (ko) * | 2019-12-18 | 2023-12-05 | 엠브릭스 주식회사 | 보툴리눔 신경 독소의 안전한 제조 방법 |
| WO2022140249A1 (en) * | 2020-12-21 | 2022-06-30 | Children's Medical Center Corporation | Improved receptor-binding domain of botulinum neurotoxin a and uses thereof |
| GB202100566D0 (en) | 2021-01-15 | 2021-03-03 | Ipsen Biopharm Ltd | Treatment of brain damage |
| CN113495106B (zh) * | 2021-02-10 | 2023-08-25 | 中国人民解放军军事科学院军事医学研究院 | 样品检测方法 |
| CN114957482B (zh) * | 2021-02-26 | 2024-09-24 | 重庆誉颜制药有限公司 | 一种经修饰的神经毒素的单链多肽及其用途 |
| GB202103372D0 (en) | 2021-03-11 | 2021-04-28 | Ipsen Biopharm Ltd | Modified clostridial neurotoxins |
| US20240158773A1 (en) * | 2021-03-15 | 2024-05-16 | Children's Medical Center Cprporation | Engineered botulinum neurotoxin a protease domain with improved efficacy |
| GB202104294D0 (en) | 2021-03-26 | 2021-05-12 | Ipsen Biopharm Ltd | Clostridial neurotoxins comprising an exogenous activation loop |
| JP2024513191A (ja) | 2021-03-30 | 2024-03-22 | イプセン バイオファーム リミテッド | 疼痛及び炎症性障害の処置 |
| KR20230155007A (ko) | 2021-03-30 | 2023-11-09 | 입센 바이오팜 리미티드 | 통증 ＆ 염증성 장애의 치료를 위한 촉매 불활성 클로스트리디움 신경독소 |
| WO2022228443A1 (en) * | 2021-04-26 | 2022-11-03 | Shanghaitech University | Intramuscular compositions of botulinum neurotoxins |
| WO2023013785A1 (ja) * | 2021-08-06 | 2023-02-09 | 花王株式会社 | Ｓｎａｒｅを活用した核酸構築物 |
| GB202116795D0 (en) | 2021-11-22 | 2022-01-05 | Ipsen Biopharm Ltd | Treatment of visceral pain |
| WO2023089343A1 (en) | 2021-11-22 | 2023-05-25 | Ipsen Biopharm Limited | Treatment of pain |
| GB202206353D0 (en) | 2022-04-29 | 2022-06-15 | Ipsen Biopharm Ltd | Treatment of cervical dystonia |
| GB202206348D0 (en) | 2022-04-29 | 2022-06-15 | Ipsen Biopharm Ltd | Treatment of limb spasticity |
| GB202206361D0 (en) | 2022-04-29 | 2022-06-15 | Ipsen Biopharm Ltd | Treatment of a facial dystonia |
| GB202206362D0 (en) | 2022-04-29 | 2022-06-15 | Ipsen Biopharm Ltd | Treatment of upper facial lines |
| EP4537850A1 (en) * | 2022-06-10 | 2025-04-16 | Medytox Inc. | Composition for stabilizing botulinum neurotoxin, botulinum neurotoxin formulation containing same, and polypeptides for use therein |
| CN115785237B (zh) * | 2022-09-01 | 2023-06-16 | 上海蓝晶生物科技有限公司 | 一种重组肉毒杆菌毒素及其制备方法 |
| GB202213479D0 (en) | 2022-09-14 | 2022-10-26 | Ipsen Biopharm Ltd | Cell-free clostridial neurotoxin assays |
| GB202214229D0 (en) | 2022-09-28 | 2022-11-09 | Ipsen Biopharm Ltd | Clostridial neurotoxins comprising an activating endosomal protease cleavage site |
| GB202214232D0 (en) | 2022-09-28 | 2022-11-09 | Ispen Biopharm Ltd | Clostridial neurotoxins comprising an activating exogenous protease cleavage site |
| JP2025534349A (ja) | 2022-09-30 | 2025-10-15 | イプセン バイオファーム リミテッド | 膀胱痛症候群の治療 |
| GB202307439D0 (en) | 2023-05-18 | 2023-07-05 | Ipsen Biopharm Ltd | Treatment of a headache disorder with botylinum neurotoxin a |
| CN116813727B (zh) * | 2023-06-08 | 2025-06-06 | 苏州德进生物制药有限公司 | 一种a型肉毒毒素的制备方法及其应用 |
| WO2025093845A1 (en) | 2023-11-01 | 2025-05-08 | Ipsen Biopharm Limited | Use of high dose chimeric botulinum toxin a for the treatment of upper facial lines |
| WO2025093844A1 (en) | 2023-11-01 | 2025-05-08 | Ipsen Biopharm Limited | Use of chimeric botulinum toxin a for treating blepharospasm and hemifacial spasm |
| GB202318884D0 (en) | 2023-12-11 | 2024-01-24 | Ipsen Biopharm Ltd | Formulation |
| GB202320108D0 (en) | 2023-12-28 | 2024-02-14 | Ipsen Biopharm Ltd | Biosensor |
| GB202404021D0 (en) | 2024-03-20 | 2024-05-01 | Ipsen Biopharm Ltd | Cell-based neurotoxin assay |
| CN118388606B (zh) * | 2024-04-25 | 2025-09-23 | 武汉大学 | 一种结合蛋白Bntifitin及其在制备用于治疗冠状病毒感染的药物中的应用 |
Family Cites Families (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4880635B1 (en) | 1984-08-08 | 1996-07-02 | Liposome Company | Dehydrated liposomes |
| US5807715A (en) | 1984-08-27 | 1998-09-15 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin |
| US4921757A (en) | 1985-04-26 | 1990-05-01 | Massachusetts Institute Of Technology | System for delayed and pulsed release of biologically active substances |
| US4920016A (en) | 1986-12-24 | 1990-04-24 | Linear Technology, Inc. | Liposomes with enhanced circulation time |
| JPH0825869B2 (ja) | 1987-02-09 | 1996-03-13 | 株式会社ビタミン研究所 | 抗腫瘍剤包埋リポソ−ム製剤 |
| US4917951A (en) | 1987-07-28 | 1990-04-17 | Micro-Pak, Inc. | Lipid vesicles formed of surfactants and steroids |
| US4911928A (en) | 1987-03-13 | 1990-03-27 | Micro-Pak, Inc. | Paucilamellar lipid vesicles |
| US5053005A (en) | 1989-04-21 | 1991-10-01 | Gary E. Borodic | Chemomodulation of curvature of the juvenile spine |
| EP0758900B1 (en) | 1994-05-09 | 2002-04-10 | BINDER, William J. | Botulinum toxin FOR REDUCTION OF migraine HEADACHE PAIN |
| GB9508204D0 (en) | 1995-04-21 | 1995-06-07 | Speywood Lab Ltd | A novel agent able to modify peripheral afferent function |
| US5721215A (en) | 1996-03-20 | 1998-02-24 | Allergan | Injectable therapy for control of muscle spasms and pain related to muscle spasms |
| US6113915A (en) | 1999-10-12 | 2000-09-05 | Allergan Sales, Inc. | Methods for treating pain |
| US20040033241A1 (en) | 2000-06-02 | 2004-02-19 | Allergan, Inc. | Controlled release botulinum toxin system |
| WO2005076785A2 (en) * | 2003-12-19 | 2005-08-25 | Wisconsin Alumni Research Foundation | Method and compositions for detecting botulinum neurotoxin |
| EP2153848A3 (en) * | 2005-01-27 | 2010-07-21 | The Regents of the University of California | Therapeutic monoclonal antibodies that neutralize botulinium neurotoxins |
| AU2006227816B2 (en) * | 2005-03-15 | 2012-04-05 | Allergan, Inc. | Modified clostridial toxins with enhanced targeting capabilities for endogenous clostridial toxin receptor systems |
| DE102005019302A1 (de) * | 2005-04-26 | 2006-11-16 | Toxogen Gmbh | Carrier zum Targeting von Nervenzellen |
| WO2008105901A2 (en) | 2006-07-11 | 2008-09-04 | Allergan, Inc. | Modified clostridial toxins with enhanced translocation capability and enhanced targeting activity |
| CN100577149C (zh) * | 2006-12-21 | 2010-01-06 | 北京民海生物科技有限公司 | 一种治疗用a型肉毒毒素冻干粉针剂新型冻干保护剂配方 |
| US8486422B2 (en) | 2007-07-26 | 2013-07-16 | Allergan, Inc. | Methods of activating clostridial toxins |
| SG181772A1 (en) | 2009-12-16 | 2012-07-30 | Allergan Inc | Modified clostridial toxins comprising an integrated protease cleavage site-binding domain |
| EP2650003B1 (en) * | 2010-05-20 | 2016-07-27 | Allergan, Inc. | Degradable clostridial toxins |
| WO2012041761A2 (en) * | 2010-09-28 | 2012-04-05 | Merz Pharma Gmbh & Co. Kgaa | Botulinum neurotoxin polypeptides exhibiting a prolonged activity |
| UA116985C2 (uk) | 2012-05-30 | 2018-06-11 | Президент Енд Феллоуз Оф Гарвард Колледж | Рекомбінантний ботулінічний нейротоксин |
| GB201312317D0 (en) * | 2013-07-09 | 2013-08-21 | Syntaxin Ltd | Cationic neurotoxins |
| WO2016110662A1 (en) * | 2015-01-09 | 2016-07-14 | Ipsen Bioinnovation Limited | Cationic neurotoxins |
| PT3274364T (pt) * | 2015-03-26 | 2021-11-05 | Harvard College | Neurotoxina botulínica manipulada |
| GB201505306D0 (en) * | 2015-03-27 | 2015-05-13 | Ipsen Biopharm Ltd | Chimeric polypeptides |
| BR112018003782A2 (pt) * | 2015-08-27 | 2018-09-25 | Ipsen Pharma Sas | composições e métodos para o tratamento da dor |
| IL263058B2 (en) * | 2016-06-08 | 2023-11-01 | Childrens Medical Center | Engineered botulinum neurotoxins |
| EP3481852B1 (en) | 2016-07-08 | 2022-12-07 | Children's Medical Center Corporation | A novel botulinum neurotoxin and its derivatives |
| EP3504226A1 (en) * | 2016-08-24 | 2019-07-03 | President and Fellows of Harvard College | Engineered botulinum neurotoxin |
| EP3312290A1 (en) * | 2016-10-18 | 2018-04-25 | Ipsen Biopharm Limited | Cellular vamp cleavage assay |
| WO2018073370A1 (en) * | 2016-10-21 | 2018-04-26 | Toxogen Gmbh | A functional detection assay devoid of antibodies for serotyping of botulinum neurotoxins |
| US20190364907A1 (en) | 2017-07-21 | 2019-12-05 | The Regents Of The University Of California | Compositions of mosquitocidal clostridial proteins and methods of use |
| WO2019067815A2 (en) | 2017-09-29 | 2019-04-04 | Children's Medical Center Corporation | NEUROTOXIN-LIKE TOXIN AND USES THEREOF |
| WO2019152380A1 (en) * | 2018-01-30 | 2019-08-08 | Children's Medical Center Corporation | Production of botulinum neurotoxins using bacillus systems |
| WO2019243376A1 (en) * | 2018-06-18 | 2019-12-26 | Ipsen Biopharm Limited | Intramuscular injection of botulinum toxin for the treatment of vulvodynia |
| GB201815817D0 (en) * | 2018-09-28 | 2018-11-14 | Ispen Biopharm Ltd | Clostridial neurotoxins comprising and exogenous activation loop |
| CA3111674A1 (en) * | 2018-09-28 | 2020-04-02 | Ipsen Biopharm Limited | Cell-based clostridal neurotoxin assays |
-
2017
- 2017-07-07 EP EP17742898.4A patent/EP3481852B1/en active Active
- 2017-07-07 JP JP2019500553A patent/JP7158371B2/ja active Active
- 2017-07-07 PL PL17742898.4T patent/PL3481852T3/pl unknown
- 2017-07-07 IL IL298102A patent/IL298102B2/en unknown
- 2017-07-07 HU HUE17742898A patent/HUE061429T2/hu unknown
- 2017-07-07 KR KR1020197003414A patent/KR102530925B1/ko active Active
- 2017-07-07 CA CA3030155A patent/CA3030155A1/en active Pending
- 2017-07-07 IL IL263754A patent/IL263754B2/en unknown
- 2017-07-07 NZ NZ749810A patent/NZ749810A/en unknown
- 2017-07-07 UA UAA201900267A patent/UA125965C2/uk unknown
- 2017-07-07 BR BR112019000278-2A patent/BR112019000278A2/pt unknown
- 2017-07-07 PT PT177428984T patent/PT3481852T/pt unknown
- 2017-07-07 FI FIEP17742898.4T patent/FI3481852T3/fi active
- 2017-07-07 CN CN201780042152.XA patent/CN109803980B/zh active Active
- 2017-07-07 US US16/315,698 patent/US11286473B2/en active Active
- 2017-07-07 DK DK17742898.4T patent/DK3481852T5/da active
- 2017-07-07 MX MX2019000151A patent/MX2019000151A/es unknown
- 2017-07-07 WO PCT/US2017/041255 patent/WO2018009903A2/en not_active Ceased
- 2017-07-07 SG SG10201912102WA patent/SG10201912102WA/en unknown
- 2017-07-07 ES ES17742898T patent/ES2939001T3/es active Active
- 2017-07-07 SG SG11201811338VA patent/SG11201811338VA/en unknown
- 2017-07-07 EP EP22211723.6A patent/EP4212545A1/en active Pending
- 2017-07-07 EA EA201990229A patent/EA201990229A1/ru unknown
- 2017-07-07 AU AU2017292922A patent/AU2017292922B9/en active Active
-
2019
- 2019-01-17 ZA ZA2019/00341A patent/ZA201900341B/en unknown
-
2021
- 2021-12-20 US US17/555,570 patent/US20220177867A1/en active Pending
-
2022
- 2022-05-09 JP JP2022076994A patent/JP7402916B2/ja active Active
- 2022-05-16 AU AU2022203264A patent/AU2022203264B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019528042A5 (https=) | ||
| FI3481852T3 (fi) | Uusi botulinum-neurotoksiini ja sen johdannaisia | |
| JP2015519362A5 (https=) | ||
| AR108689A1 (es) | Neurotoxinas clostridiales quiméricas | |
| JP2019216735A5 (https=) | ||
| JP2019523015A5 (https=) | ||
| JP2024012421A5 (https=) | ||
| RU2017134357A (ru) | Сконструированный ботулинический нейротоксин | |
| AR132701A2 (es) | Neurotoxinas catiónicas | |
| JP2021514674A5 (https=) | ||
| CN103228286A (zh) | 可降解梭菌毒素 | |
| RU2015107240A (ru) | Способ производства протеолитически процессированных полипептидов | |
| JP2015536654A5 (https=) | ||
| EP2424884B1 (en) | A novel subtype of clostridium botulinum neurotoxin type a and uses thereof | |
| JP2019533430A5 (https=) | ||
| JP2024512397A5 (https=) | ||
| JP2016513082A5 (https=) | ||
| CA3051785A1 (en) | Improved use of botulinum neurotoxin in the treatment of sialorrhea | |
| WO2009015840A2 (en) | Polypeptide for targeting of neural cells | |
| TW201718627A (zh) | 重組梭菌神經毒素及其使用與形成方法、包括其之醫藥組合物及對應其之前驅物、編碼前驅物之核酸序列及其獲得方法與前驅物之形成方法、載體與包括核酸序列之重組宿主細胞 | |
| US11952601B2 (en) | Recombinant botulinum toxin with increased duration of effect | |
| JP2024107016A (ja) | ボツリヌス神経毒素ａサブタイプ６および薬理学的使用方法 | |
| US11453903B2 (en) | Production of activated clostridial neurotoxins | |
| RU2019108257A (ru) | Сконструированный ботулинический нейротоксин | |
| RU2020131317A (ru) | Биогибрид ботулинического нейротоксина |